Pasithea Therapeutics Corp. Income Statement
KTTA|2 years of annual SEC 10-K data (FY2021-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Pasithea Therapeutics Corp. reported $15,062 in revenue and $2M in net loss for FY2022. Revenue increased 0.0% from FY2021 to FY2022.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.26 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 |
|---|---|---|
| Revenue | $15.1K | $15.1K |
| Cost of Revenue | $17.3K | $17.3K |
| Gross Profit | - | -$2.2K |
| SG&A Expense | $4.5M | $41.0K |
| R&D Expense | $2.7M | - |
| Operating Income | -$4.5M | -$41.0K |
| Interest Expense | $508 | -$508 |
| Net Income | -$2.2M | -$41.0K |
| EPS (Basic) | -$0.21 | $0.00 |
| EPS (Diluted) | -$0.21 | - |
| Shares Outstanding | 23.0M | 7.5M |
| Gross Margin | - | -14.7% |
| Operating Margin | -29925.7% | -272.1% |
| Profit Margin | -14430.5% | -272.1% |